Maria Teresa Cedena

Maria Teresa Cedena is a hematologist specializing in the biology and clinical management of smoldering multiple myeloma (SMM) and early plasma cell dyscrasias. She has contributed to the GEM-CESAR trial investigating aggressive early intervention in high-risk SMM with carfilzomib-lenalidomide-dexamethasone, achieving deep responses and potential functional cures. Her work on minimal residual disease monitoring by next-generation flow cytometry has helped define response endpoints in SMM clinical trials. She represents the Spanish Myeloma Group (PETHEMA/GEM) at international myeloma consortia.